Stocktoria
Jiangsu Hengrui Pharmaceuticals Co.,Ltd 600276.SS
CN · Shanghai Stock Exchange · XSHG · stock · Healthcare · website
Jiangsu Hengrui Pharmaceuticals Co.,Ltd financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | CN¥31.6B | CN¥28.0B | CN¥22.8B | CN¥21.3B |
| Gross profit | CN¥27.3B | CN¥24.1B | CN¥19.3B | CN¥17.8B |
| R&D expense | CN¥7.0B | CN¥6.6B | CN¥5.0B | CN¥4.9B |
| SG&A expense | CN¥7.4B | CN¥7.2B | CN¥6.5B | CN¥6.2B |
| Operating income | CN¥8.6B | CN¥6.8B | CN¥4.6B | CN¥3.3B |
| Interest expense | CN¥14.3M | CN¥5.6M | CN¥5.9M | CN¥6.5M |
| Income tax | CN¥990.6M | CN¥832.7M | CN¥389.3M | CN¥153.4M |
| Net income | CN¥7.7B | CN¥6.3B | CN¥4.3B | CN¥3.9B |
| EPS (diluted) | CN¥1.18 | CN¥1.00 | CN¥0.68 | CN¥0.61 |
| Operating cash flow | CN¥11.2B | CN¥7.4B | CN¥7.6B | CN¥1.3B |
| Free cash flow | CN¥8.3B | CN¥5.5B | CN¥6.2B | -CN¥726.9M |
| Cash & equivalents | CN¥41.0B | CN¥24.8B | CN¥20.7B | CN¥15.1B |
| Inventory | CN¥2.9B | CN¥2.4B | CN¥2.3B | CN¥2.5B |
| Total assets | CN¥69.9B | CN¥50.1B | CN¥43.8B | CN¥42.4B |
| Total debt | CN¥74.2M | CN¥110.2M | CN¥75.2M | CN¥1.4B |
| Total liabilities | CN¥8.1B | CN¥4.0B | CN¥2.8B | CN¥4.0B |
| Shareholders' equity | CN¥61.3B | CN¥45.5B | CN¥40.5B | CN¥37.8B |
Growth · year-over-year · Revenue CAGR 14.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +13.0% | +22.6% | +7.3% | — |
| Net income growth | +21.7% | +47.3% | +10.1% | — |
| EPS growth | +18.0% | +47.1% | +11.5% | — |
| Free cash flow growth | +51.7% | -11.5% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.